Nanobody Shows Promise in Myasthenia Gravis
(MedPage Today) -- Results from the phase III PREVAIL trial presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting showed that treatment with the investigational once-weekly nanobody...
Lean: Center
Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Coverage breakdown
Funding
Corporate
Countries
United States
Media ownership
Independent
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported)
Propaganda risk: 0
Trending: Low
Sources: 1
Reliability: 65
Bias severity: 0
Risk: 0Sentiment: 0Sensationalism: 0
Amplification: 0